Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 9Triple Negative Breast Neoplasms 5Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma 1Liposarcoma 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HR+HER2- Breast Cancer 1Colorectal Neoplasms 1

Interventions

Radiotherapy 3Radiation 3palbociclib 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Doxorubicin 2zimberelimab 1talimogene laherparepvec 1sotigalimab 1ribociclib 1pazopanib 1eribulin 1enzalutamide 1durvalumab 1cemiplimab 1abemaciclib 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Midazolam 1Letrozole 1Ipilimumab 1Ifosfamide 1Fulvestrant 1Everolimus 1Disulfides 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Liposarcoma × eribulin × Clear all
NCT03361436 2026-04-08

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 1 Active not recruiting
15 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡